Global Henatologic Malignancies Testing Market 2026 – 2035

It is projected that the global Henatologic Malignancies Testing market size will be USD 3.28 billion in 2025, and it is also projected that the market size will increase to USD 3.72 billion in 2026, and to approximately USD 12.47 billion in 2035, at an annual CAGR of 14.4%. There are rising incidences of blood cancers like leukemia, lymphoma, and multiple myeloma, which are contributing to the growth of the market as well as the demand for early and accurate diagnostic solutions.

The improvement in molecular diagnostics and the use of next-generation sequencing (NGS) and minimal residual disease (MRD) testing is greatly enhancing the process of detection and treatment planning.

Market Highlight

• Asia Pacific was the market leader in the Hematologic Malignancies Testing, featuring a market share of 45%.

• The North American region will expand at a rate of 14.3% from 2026 to 2035.

• The kits segment comprised the biggest portion of the market in 2025, with a volume of approximately 70-80%, associated with the significant adoption by routine diagnostics, standard workflows, and large volume capability needs.

• By product, the services division would experience the highest growth over the forecast period, which will be facilitated by growing demand for outsourced testing and a high level of genomic profiling and analysis powered by bioinformatics.

• The flow cytometry segment would make up the biggest portion of the market in 2025 by platform, being 48.5%, due to its extensive application in leukemia diagnosis, faster turnaround, and clinical utility.

• By platform: The next-generation sequencing (NGS) segment will experience the highest growth rate in the forecast period and will be aided by the growing use of precision medicine, decreasing costs of sequencing, and an increasing demand for in-depth profiling of the genome.

• End-use-wise, the diagnostic laboratories segment was the largest segment with the highest market share of 43.6% in 2025 as a result of a huge volume of testing, advanced infrastructure, and growth in outsourcing of complex diagnostics.

• By end use, the segment of reference laboratories is expected to increase at the highest rate because of the increasing demand for specialized testing like MRD detection, genomic profiling, and complicated mutation detection.

Significant Growth Factors

The current market trend of the Henatologic Malignancies Testing has a great growth opportunity because of a number of reasons:

• Increased Incidence of Blood Cancers and Aging Population: There is an increasing burden of hematologic malignancies, namely leukemia, lymphoma, and multiple myeloma, which is a primary demand factor of testing worldwide. The worldwide cancer statistics have indicated that blood cancers represent greater than 10 percent of the entire cancer cases and leukemia alone provides more than 470,000 novel cases yearly. It is highly prevalent among the elderly where almost 60 percent of the cases are diagnosed in individuals who are more than 60 years of age. The number of patients that will need diagnostic tests is growing at an alarming rate as the global geriatric population is expected to reach 2.1 billion in 2050. It is also essential that diagnosis and treatment be initiated as soon as possible since even a 30-40 percent chance of survival is achieved with early and accurate diagnosis. This has seen a rise in the use of routine screening and high level diagnostic assays in all hospitals and oncology centers hence promoting the continuous growth of the hematologic malignancies testing market.

• Technological Innovations in Molecular Diagnostics and Personalized Medicine: The current technological innovation in hematologic malignancy testing, molecular diagnostics, is considerably altering the scene in the field. Delivery of precise information on genetic mutation and chromosomal abnormality can be done through techniques like next-generation sequencing (NGS), polymerase chain reaction (PCR), and flow cytometry. Research has shown that more than 60-70 percent of leukemia instances are linked with definite genetic mutations like BCR-ABL, FLT3, and NPM1, and hence molecular testing is necessary in the diagnosis and treatment planning. The introduction of personalized medicine has further added to the dependency on these technologies because the targeted therapy needs the accurate identification of biomarkers. Also, NGS-based testing is able to test multiple genes at the same time decreasing the diagnostic turnaround time by 50 or more. Efficiency and accuracy are also increasing because of the introduction of artificial intelligence in the diagnostic processes. Not only are these developments improving clinical outcomes but also they are increasing the use of advanced testing solutions worldwide.

• Growing Interest in Minimally Invasive and Speedy Diagnostic Technology: There is a growing demand for liquid biopsy and minimally invasive diagnostic techniques in the hematologic malignancies diagnostic field. With Liquid biopsy, it is now possible to identify circulating tumor DNA (ctDNA) using a simple blood sample, eliminating the invasive bone marrow biopsies. Research indicates that liquid biopsy has the potential to monitor disease relapse at least 3-6 months before other diagnostic approaches with better clinical decision-making. Moreover, fast diagnostic tests are gaining more significance in the oncology practice whereby early intervention is very essential in saving lives. Turnaround time of complex diagnostic tests is also greatly decreased and some molecular tests can have results available within 24-48 hours. This pace is vital in aggressive malignancies, e.g. acute leukemia, where the time of treatment has the ability to influence the results. These new diagnostic methods are being adopted with great enthusiasm because of the combination of enhanced patient comfort, quicker and more efficient outcomes, and enhanced monitoring capabilities.

What are the Major Advances Changing the Henatologic Malignancies Testing Market Today?

• Next-Generation Sequencing (NGS) and Comprehensive Genomic Profiling: A major innovation in the hematologic malignancy testing sector is the prevalence of next-generation sequencing (NGS) as a method of comprehensive genomic profiling. NGS permits massively parallel analysis of hundreds of genes, and such mutations of interest as BCR-ABL, FLT3, NPM1, and JAK2 can be identified that are essential to diagnosis, prognosis, and choice of therapy. Research has shown that in clinical decision-making, actionable genetic alterations are observed in more than 65.75% of hematologic cancer cases, and therefore genomic testing is imperative. Over conventional approaches, NGS minimizes the diagnostic turnaround time by approximately 40-50 as well as enhances the sensitivity and accuracy. It also allows low levels of minimal residual (MRD) to be detected at extremely low levels (less than 0.01 percent), allowing detection of early relapse. With the growing field of precision oncology, NGS-based panels have become the norm in oncology centers, which has greatly enhanced patient stratification and has led to the demand for high-quality molecular diagnostics worldwide.

• Flow Cytometry Innovations and Minimal Residual Disease (MRD) Surveillance: The improvements in multiparameter flow cytometry are making tremendous contributions towards the detection and monitoring of hematologic malignancies. Recent flow cytometry methods are capable of analyzing 8 or more markers at a time, including an ability to do specific immunophenotyping of cancer cells. This is especially significant in the diagnosis of leukemia and lymphoma, the correct classification of which directly influences the choice of treatment regimen. Moreover, one cancer cell among 10,000-100,000 normal cells (sensitivity of 10-13 to 10-15) can be detected by MRD monitoring with the use of flow cytometry, thus becoming a strong tool for measuring treatment response. Of clinical interest, it has been demonstrated that MRD-negative patients have a progression-free survival of up to 2-3 times that of MRD-positive patients. Those capabilities enable clinicians to modify therapy on a real-time basis and minimize the risk of relapses. The adoption of complex flow cytometry technology in hematology diagnostics is spreading due to the growing adoption of MRD testing in clinical guidelines.

• Liquid Biopsy and Non-Invasive Diagnostic Innovations: Liquid biopsy is a significant upcoming innovation in the field of testing of hematologic malignancies and presents a minimally invasive substitute to the conventional bone marrow biopsy. This method examines circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomes in blood samples in order to monitor disease in real-time. Research indicates that liquid biopsy is capable of identifying relapse 3-6 months before the traditional diagnostic methods, hence improving a greater number of patients. It is also suitable in terms of being able to sample frequently, and this is essential in monitoring disease course and response to treatment. Moreover, liquid biopsy minimizes discomfort and procedural risks in invasive methods of patients. The technology is found to be especially useful in such situations as lymphoma and multiple myeloma where the heterogeneity of tumors is great. As the sensitivity and specificity of assays continue to increase, liquid biopsy will be implemented as a routine procedure in the diagnostics of cancer in the hematologic field.

• Artificial Intelligence (AI) and Digital Pathology: Artificial intelligence (AI) and digital pathology are changing the accuracy of diagnoses and efficiency of work in the field of testing of hematologic malignancies. AI can be used on big data, such as genomic data, histopathology slides, and clinical records, to extract patterns that are not easy to discern by human observers. Research shows that AI-aided diagnostics can increase accuracy by up to 15-20 percent, and it can decrease interpretation time by nearly 30 percent. The AI tools are utilized in hematopathology to perform automated cell classification, abnormal cell morphology detection, and disease prognosis. Moreover, digital pathology is useful in remote analysis and collaboration by enhancing the availability of expert diagnosis in underserved areas. These technologies are automating the work of laboratories, eliminating diagnostic errors, and assisting in unique treatment methods, which are pushing the market to new heights.

• Companion Diagnostics and Targeted Therapy Alignment: The rapid development of targeted therapy in Hematologic malignancies has resulted in major developments in companion diagnostics. These tests aim at detecting certain biomarkers that will define patient eligibility to receive specific therapies to treat cancer, including tyrosine kinase inhibitors, monoclonal antibodies, and CAR-T cell therapies. Indicatively, chronic myeloid leukemia is treated by detecting BCR-ABL fusion, whereas immunotherapy is determined by CD19 and CD20 markers. It has been estimated that over 40-50 percent of new oncology drugs are developed, together with companion diagnostic tests, and their role is paramount to these drugs. In addition to enhancing the efficacy of treatment, companion diagnostics helps to minimize adverse effects by proper selection of the patient. Regulatory encouraging co-development of drugs and diagnostics is also swiftly enhancing innovativeness, and companion diagnostics are becoming the foundation of precision treatment in malignancies of the blood.

Category Wise Insights

By Product

Why Kits Dominate the Market?

The leading category in the hematologic malignancies testing market is kits, since they are widely applied in routine diagnostics and standardized laboratory and hospital protocols. Such kits as PCR, immunoassay, and NGS-based panels can be used to conduct tests that are accurate, reproducible, and at a high throughput level, which is essential due to the increasing global incidence of blood cancers. It is approximated that more than 70-80 percent of the initial diagnostic testing is based on kit based detecting biomarkers and genetic profiling. They are also very scalable to large sample volumes due to their ease of use, regulatory approvals, and compatibility with automated platforms. Also, the growing availability of companion diagnostic kits in line with targeted therapies is also enhancing adoption. Kit protocols are much more cost-effective, decentralized, and quicker than the services, which require outsourcing and a longer turnaround time, and thus can be used in any diagnostic environment.

The services are in the rapidly expanding market of hematologic malignancy testing because the quantity of specialized and outsourced diagnostic solutions is growing. More complex testing like high-end genomic profiling and MRD analysis, may need complex infrastructure and expertise, making health care providers outsource. This practice has even been enhanced by the increasing use of next generation sequencing and bioinformatics-based analysis with almost 50-60 percent of complex oncology tests currently being outsourced to specialized laboratories. Moreover, with the development of personalized medicine and companion diagnostics, the number of situations that require an interpretation based service, instead of a single kit, is growing. End-to-end solutions such as sample processing, analysis, and clinical reporting are also provided by service providers to enhance efficiency in the hospitals. With the growth of complexity of testing and care systems oriented to cost optimization, the services segment is likely to experience acute growth in the world.

By Platform

Why Flow Cytometry is the Best of the Market?

The hematologic malignancies testing market is dominated by flow cytometry because of the very important role it plays in the diagnosis, classification, and monitoring of the disease, especially in leukemia and lymphoma. It is a technology that allows one to analyze several cellular markers simultaneously, which permits the use of this technology to perform accurate immunophenotyping of cancer cells. Flow cytometry is a hematological diagnostic tool, and it is the cornerstone of clinical diagnosis of leukemia in more than 80% of cases. It gives prompt outcomes, in most cases within hours, which is very necessary in aggressive cancers that need urgent decisions on treatment. Moreover, the fact that it is widely represented in hospitals and diagnostics laboratories, and its cost is relatively lower in comparison with the sophisticated genomic platforms, facilitates its dominance. Although it may be replaced by other technologies like NGS and FISH that offer more detailed molecular data, flow cytometry is the initial diagnostic method because of its rapidity, consistency, and clinical history.

The upcoming platform that is expanding rapidly in the hematologic malignancies testing market is next-generation sequencing (NGS) because it provides a voluminous amount of genomic information in a single test. NGS has the potential to identify several mutations at once, and results suggest that 65.75 percent of hematologic cancers have actionable genetic changes. This is also because the technology is sensitive enough to detect minimal residual disease (MRD) at a level less than 0.01 which is important in relapse monitoring. Besides, the price of sequencing has also reduced by more than 80 percent in the last ten years, and therefore, it has become more accessible. The trend that leads to the use of NGS is the development of precision medicine and targeted therapies, where clinicians need detailed molecular information to make treatment decisions. Although classical methods are still compulsory, the rapid development of NGS is happening worldwide with the help of scalability, accuracy, and increasing clinical uses.

By End Use

The Diagnostic Laboratories Are Ruling the Market?

The hematologic malignancy testing market is controlled by diagnostic laboratories since they have the capacity to deal with large volumes of testing with the capability of high technology. Such laboratories have advanced platforms like flow cytometry, NGS, and molecular diagnostics that provide the ability to effectively and thoroughly test cancer. It is approximated that more than 60-70 percent of tests of hematologic malignancy are carried out in centralized labs, as they are cost-effective and have specialization. Moreover, hospitals are increasingly using the services of these laboratories to outsource the services of the complex diagnostic processes to ease the operational load and enhance the turnaround time. Automation and standardized procedures are also of benefit to diagnostic laboratories in terms of giving consistent and reliable results. Although hospitals and specialty clinics are important in sample collection and primary diagnosis, diagnostic laboratories are the most scalable and technologically skilled and thus make the most sense to be the end-use segment.

The fastest-growing end-use segment in the market of testing in hematologic malignancies is the reference laboratories, as they specialize in the most complicated and high-end diagnostic services. The facilities of these laboratories are concentrated on sophisticated diagnoses like genomic profiling, examination of rare mutations, and MRD, which entails extremely trained staff and high-tech equipment. Due to the growing popularity of precision medicine, there is growing demand to carry out specialized testing, with almost 40-50 percent of advanced diagnostics in oncology referring to such facilities. Smaller hospitals and regional labs are also assisted with reference labs to have access to advanced tests that cannot be performed in-house. Moreover, the increasing pattern of lab networks and partnerships across the globe is increasing their scope. The rapid growth of the reference laboratories is likely to be the most rapid one in the nearest future because the sophistication of the diagnostics of the hematologic cancers is constantly growing.

Report Scope

Regional Analysis

Why did Asia Pacific Take Over the Market in 2025?

Asia Pacific has market dominance in terms of hematologic malignancies testing market because of its market size with a large patient population, increasing cancer burden, and improving health care infrastructure. The region contributes close to 40-45 percent of the total world population, and this percentage contributes significantly towards the rising prevalence of blood cancers like leukemia and lymphoma.

The rapid aging is observed in such countries as China, India, and Japan, and it is projected that the number of elders will be over 600 million by 2030 that contributes to the greater cancer risk. Also, the volumes of tests are being pushed by the improvement of the access to diagnostic services and the increase in awareness about early cancer diagnosis. Adoption is also being facilitated by government programs on cancer screening and increasing healthcare spending, which is increasing at 6 to 8 percent every year in the emerging economies. The growth of the diagnostic laboratories and the availability of high-tech equipment, including flow cytometry and molecular diagnostics, are reinforcing the position of the Asia Pacific on the market.

China Market Trends

China is one of the biggest markets for hematologic malignancy testing, as it has a huge burden of cancer and it has a growing healthcare sector. More than 4 million new cancer cases are reported in the country every year, and blood cancers occupy a significant part of the list. The demographic trend of extended lifespan (more than 200 million individuals over 65 years old) poses a strong demand for cancer diagnostics. Also, the sixth-wave growth of tertiary hospitals and diagnostic laboratories is enhancing the availability of advanced technologies in testing including NGS and PCR. The early diagnosis and treatment are being catalyzed by government healthcare reforms and investments made in oncology infrastructure. The cost is also decreasing and accessibility is also improving due to domestic production of diagnostic kits and use of precision medicine that is increasing. Moreover, the increased awareness of early detection and screening initiatives is increasing the volume of tests in both rural and urban areas.

What is the Reason behind the Continued Growth in North America?

The testing market in the US is stable and gaining momentum in terms of growth in the hematologic malignancies testing market because of the developed healthcare systems, high awareness and high use of newer diagnostic technologies in North America. Blood cancer is very high in the region with leukemia, lymphoma and myeloma all contributing more than 180,000 incidences each year. There is a large adoption of early diagnosis and precision medicine practices, which leads to the need for molecular and genetic testing. Also, the application of novel diagnostics like NGS and MRD testing is backed by well-developed clinical guidelines and reimbursement frameworks. The existence of superior diagnostic corporations and ongoing research on cancer also supports the growth of the market. The growing application of companion diagnostics and targeted therapies is also driving up the demand for testing because the proper identification of biomarkers is necessary to select and monitor treatments.

How Large is the U.S. Market?

The hematologic malignancies testing market in the U.S. is dominated by a large rate of cancer of blood and high testing diagnostic level. Over 60,000 new cases of leukemia and over 90,000 cases of lymphoma are reported in the country every year presenting a high demand for diagnostic testing. Having a well-developed healthcare system and a high level of advanced technologies being generally available, the rates of testing implementation have been high in hospitals and laboratories alike. The rising attention to the early diagnoses and the individual treatment is adding to the pressure on the molecular diagnostics and genomic profiling even further. Also, the fact that major diagnostic companies and research institutes exist encourages constant test development in the way of testing. There are also robust reimbursement policies in the U.S. market, which allows the expanded access to the latest diagnostic solutions and allows further development of the market in the country.

U.S. Market Trends

The American market is highly adept with regard to the use of advanced diagnostic technologies and precision medicine strategies. The application of molecular testing, such as NGS and PCR, continues to gain popularity in providing correct diagnoses and management in the form of treatment planning of a hematologic malignancy. Research has shown that more than 70 percent of the treatment decisions made for cancer in the U.S. depend on the outcomes of diagnostic tests. Minimal residual disease (MRD) testing is also becoming increasingly popular and allows detecting the relapse early and improving patient outcomes. Furthermore, the process of artificial intelligence integration and digital pathology is improving the effectiveness of the diagnostic process and efficiency. Automated and high-throughput systems are becoming a trend in hospitals and laboratories to deal with increasing test volumes. Ongoing clinical research and effective regulatory encouragement are further stimulating innovation and the usage of sophisticated hematologic malignancy testing remedies in the country.

Why is Europe Obsessed with Efficiency and Clinical Standardization?

Europe is also considered to be a major market in the testing of hematologic malignancies mainly because of the aging population and focus on evidence-based and standard healthcare practices. In most European countries, the proportion of individuals over 65 years of age is greater than 20 percent of the population, which contributes to the rise of blood cancers and the need to conduct diagnostic testing. The region adheres to rigorous clinical protocols that encourage early diagnosis and application of advanced molecular diagnostics in order to classify a disease. Cost-efficiency and optimal resource use are the priorities of the public healthcare systems, leading to the use of high-precision testing methods like flow cytometry and NGS. Also, the high rates of screening programs and effective regulation structures contribute towards a steady demand within the region. The growth of the market in Europe is also being increased by the growing attention to personalized medicine and the incorporation of companion diagnostics.

Germany Market Trends

Germany is one of the European markets because it has a well-developed healthcare system and embraces new diagnostic technology. The number of hematologic cancer cases in the country is large every year, which predetermines the need to find the correct and timely diagnosis. Germany has a well developed system of diagnostic labs that have advanced platforms which include flow cytometry and molecular testing systems. Powerful reimbursement policies and focus on high-quality healthcare services favor the popularity of these technologies. Also, there is an expanded use of precision medicine and genomic profiling which is enhancing patient outcomes. New research centers and alliances with international diagnosis corporations are also contributing to innovation. Germany is also an important exporter to the European hematologic malignancies testing market as the use of digital pathology and AI-based tools is improving the efficiency of diagnosis.

Why is the Middle East & Africa Region Growing?

The hematologic malignancies testing segment in the Middle East area of Africa is growing because of the advancement of the healthcare infrastructure and the increase in awareness about cancer diagnosis. Diagnostic services are in demand because of increasing rates of blood cancers as well as increased population. The amount of healthcare expenditure in most of the gulf countries is growing enormously, and it is in favor of the deployment of sophisticated diagnostic technologies. Moreover, the governmental activities focusing on enhancing the cancer treatment and its early diagnoses are also adding to the market growth. Low access to healthcare in Africa has traditionally limited its growth, but continued investments in diagnostic centers and international cooperation are raising the level of accessibility. Although the market is at the stage of formation, the awareness, the expansion of laboratory networks, and the slow penetration of the advanced methods of testing are predicted to deliver the stabilized growth in the region.

Top Players in the Market and Their Offerings

• Abbott Laboratories

• Adaptive Biotechnologies

• ARUP Laboratories

• Bio-Rad Laboratories Inc.

• ICON plc

• Illumina Inc.

• Invivoscribe Inc.

• Laboratory Corporation of America Holdings

• NeoGenomics Laboratories

• OHSU’s Knight Diagnostic Laboratories

• QIAGEN N.V.

• Quest Diagnostics

• Sysmex Corporation

• Tempus Labs Inc.

• Bio-Techne

• DiaSorin S.p.A

• Thermo Fisher Scientific Inc.

• Bruker Corporation

• Vela Diagnostics

• Amoy Diagnostics Co. Ltd.

• Integrated DNA Technologies Inc.

• Others

Key Developments

The market has undergone immense transformation, where the industry players are striving to expand their abilities and come up with product portfolios.

• FusionMRD: Pairidex has stated FusionMRD, an individualized RNA-based digital PCR assay designed to assess quantifiable residual disease (MRD) on fusion-driven hematologic cancers, will be available in November 2025. The assay has a limit of 0.001% using peripheral blood and hence is ultra-high sensitivity and capable of detecting relapses early in patients with leukemia and helps in monitoring the disease to a greater level of accuracy.

• Since October 2025, Integrated DNA Technologies, Inc. has been developing automated customizable next-generation sequencing (NGS) workflows along with Hamilton in order to have complete genomic profiling. These platform-independent solutions developed as a result of technology supplied by Hamilton on the liquid handling platforms can enhance the efficiency and scalability of applications in solid tumor and hematologic cancer research.

The strategic activities have seen the companies consolidate their market positions, expand their product lines, upgrade their technology, and take advantage of their growth opportunities in the emerging marketplace.

The Henatologic Malignancies Testing Market is segmented as follows:

By Product

• Kits

• Services

By Platform

• Next-Generation Sequencing

• Fluorescence In-Situ Hybridization

• Immunohistochemistry

• Flow Cytometry

• Other

By End Use

• Specialty Clinics and Hospitals

• Diagnostic Laboratories

• Reference Laboratories

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America